Best in Biotech 8 Feb 2024 Fourteen biotech companies spearheading the antibody drug conjugate industry The antibody-drug conjugate market has gained significant traction recently. Discover some of the top ADC companies in the industry. February 8, 2024 - 18 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Weekly Roundup 15 Dec 2023 Pharvaris’ $300 million public offering; Genentech’s breast cancer trial success; new neuromuscular disease target discovered What’s been going on in the world of biotech of late? Find out with Labiotech’s weekly roundup of the latest biotech news. December 15, 2023 - 14 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Weekly Roundup 8 Dec 2023 Xenon’s $345 million public offering; EyePoint Pharmaceuticals’ trial success; gene therapy found to reduce liver cancer What’s been going on in the world of biotech of late? Find out with Labiotech’s weekly roundup of the latest biotech news. December 8, 2023 - 14 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2023 BIO-Europe 2023: top ten highlights The biopharma community met at Munich in Germany for BIO-Europe 2023, where attendees from across the world took part in networking events to foster collaboration, last month. With a turnout of nearly 6000 participants and more than 150 exhibitors, the event hosted a number of panel discussions. In collaboration with our parent company, life science […] December 7, 2023 - 24 minutesmins - By Dylan Kissane Share WhatsApp Twitter Linkedin Email
News and Trends 1 Dec 2023 Arvinas raises $350 million; Exonate’s trial reaps success; new cancer drugs discovered Here is Labiotech’s weekly roundup of the latest biotech news. Stay in the loop by subscribing to our newsletter for direct updates to your inbox. The latest biotech news in fundraising In the news this week, biotech Arvinas raises $350 million PIPE American protein degradation company Arvinas has bagged $350 million in a private placement (PIPE). The […] December 1, 2023 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Weekly Roundup 24 Nov 2023 Viva’s $210 million round; Merck grabs Caraway for $610 million; Genentech signs a deal with NVIDIA Here is Labiotech’s weekly roundup of the latest biotech news. Whether it is partnerships, clinical trials, or fundraising, we have got you covered. Stay in the loop by subscribing to our newsletter for direct updates to your inbox. Viva Biotech closes $210 million funding round Chinese company Viva Biotech closed a funding round worth $210 […] November 24, 2023 - 14 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 20 Nov 2023 M&As: what’s up with the ADC buying spree? Antibody drug conjugates (ADCs) have been much sought-after through investments of late, with big pharma eyeing these drugs developed by various biotechs, to eventually nab them. With yet another ADC being bought by Bristol Myers Squibb, and AbbVie’s proposed $10 billion deal to seize ImmunoGen’s oncology pipeline, are these drugs the golden ticket to targeted […] November 20, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 17 Nov 2023How can life-saving vaccines be more affordable? Phenotypeca, a biotech business from Nottingham, UK, has been working with the Bill & Melinda Gates Foundation to produce albumin for low and middle-income countries (LMICs), offering a catalyst for making life-saving vaccines affordable globally. Global vaccine production faces several challenges. Limited availability and the high costs associated with recombinant albumin act as a barrier […] November 17, 2023 Share WhatsApp Twitter Linkedin Email
In Depth 15 Nov 2023 Beyond oil and gas: Biotech’s significant place in the Qatar Investment Authority’s strategy Since 2020, the Qatar Investment Authority (QIA) has been taking part in important biotech fundings reaching its peak in 2021 and remaining strong in 2023. They recently led a $250 million round in the company BridgeBio specialized in transformative medicine for patients suffering from cancer or genetic diseases. This investment is not an isolated case […] November 15, 2023 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Weekly Roundup 10 Nov 2023 Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs You are reading Labiotech’s weekly roundup of the latest biotech news. Korro Bio and Frequency Therapeutics close merger Last Friday, Korro Bio announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. and the entity formerly known as Korro Bio. The combined company will now operate under the name Korro Bio, Inc. […] November 10, 2023 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 2 Nov 2023 How French pharma giant Sanofi is betting big on AI The benefits of artificial intelligence (AI) in shaping clinical research and trials have given rise to many new AI-driven biotech startups. According to a recent report, the number of AI companies involved in drug discovery and development increased from 62 in 2011 to 400 in 2022. This AI-driven transformation is catching the attention of big pharma […] November 2, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 28 Sep 2023 Obesity drug success sparks biotech buying spree The last few months have seen the obesity drug market soar, after new weight loss and diabetes drugs like Novo Nordisk’s Wegovy and Ozempic took the world by storm with their incredible efficacy at inducing weight loss. These new drugs belong to a class of medications called GLP-1 analogs (or incretin-based therapies), which work by […] September 28, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email